Panuveitis: Understanding Diffuse Eye Inflammation
Understanding Panuveitis
The uvea is a highly vascular layer that lines the inside of the eye's outer wall. It has three connected parts that work together to nourish and support the eye. The iris controls how much light enters the eye. The ciliary body produces aqueous humor, the clear fluid that feeds structures in the front of the eye. The choroid provides blood supply and nourishment to the outer layers of the retina.
Although these three structures are in different parts of the eye, they form one continuous layer. This close connection means that inflammation affecting one part can spread to the others. When all three parts become inflamed at the same time with no single area more affected than the others, the condition is called panuveitis or diffuse uveitis.
Uveitis is classified based on which part of the uvea is inflamed. Anterior uveitis affects the front of the eye, mainly the iris. Intermediate uveitis targets the middle area, including the vitreous gel. Posterior uveitis involves the choroid and retina at the back of the eye. Panuveitis is distinct because it involves all of these areas at once.
This widespread inflammation makes panuveitis particularly challenging to manage. Because every part of the uvea is affected, the condition can produce a wide range of symptoms and complications. It requires careful evaluation and often more aggressive treatment than uveitis limited to a single location.
Panuveitis can result from several different causes. Infectious agents such as bacteria, viruses, fungi, and parasites can trigger inflammation throughout the uvea. Autoimmune disorders, where the body's immune system mistakenly attacks its own tissues, are another common cause. In many cases, no specific cause is found, and the condition is classified as idiopathic.
Two systemic diseases are particularly associated with panuveitis:
- Behcet disease is a multisystem condition characterized by recurring mouth sores, genital ulcers, and panuveitis. It is most common in patients from Turkey, the Middle East, and the Far East.
- Sarcoidosis is a chronic disorder that produces clusters of inflammatory cells called granulomas. It is one of the most common systemic associations with panuveitis and is more common in colder climates and among people of Black ethnicity.
Who Is Affected and Risk Factors
Uveitis in all its forms accounts for 5% to 20% of blindness in the United States and Europe, and up to 25% of blindness in developing countries. The mean prevalence of infectious panuveitis specifically is approximately 4.4 per 100,000 persons in the United States (PLOS ONE, 2020). Uveitis overall is less common in children, occurring in about 30 cases per 100,000 compared to 93 per 100,000 in adults (AAO). Panuveitis and posterior uveitis together represent roughly 14% to 21% and 6% to 30% of pediatric uveitis cases, respectively (AAO).
The risk of infectious uveitis increases significantly with age. Each decade of life beyond age 18 raises the odds by more than three times (PLOS ONE, 2020). Women have a slightly higher risk than men, with an odds ratio of 1.2 (PLOS ONE, 2020). Non-Hispanic white individuals show somewhat higher prevalence of infectious uveitis compared to other racial groups (PLOS ONE, 2020).
Certain ethnic backgrounds carry additional risk depending on the underlying cause. Behcet disease is most prevalent among populations from Turkey and the Far East. Sarcoidosis-related panuveitis is more common among people of Black ethnicity.
Several medical conditions significantly increase the risk of developing panuveitis. HIV infection raises the odds of infectious uveitis substantially, with an odds ratio of 6.4 (PLOS ONE, 2020). Rheumatologic diseases, including conditions like lupus and rheumatoid arthritis, also increase risk with an odds ratio of 1.9 (PLOS ONE, 2020).
Other factors that may raise your risk include:
- Existing autoimmune diseases such as sarcoidosis, Behcet disease, or Vogt-Koyanagi-Harada syndrome
- Exposure to infectious agents, particularly in immunocompromised individuals
- History of ocular trauma or eye surgery
- Genetic predisposition, especially in populations with higher rates of associated systemic diseases
Signs and Symptoms
Because panuveitis affects all parts of the uvea, it produces symptoms associated with anterior, intermediate, and posterior uveitis combined. Most patients experience multiple symptoms at the same time, though the severity can vary from person to person.
Common symptoms include:
- Eye pain that may range from mild aching to severe discomfort
- Photophobia (increased sensitivity to light)
- Blurred or decreased vision
- Floaters, which appear as spots, threads, or cobwebs drifting across your field of vision
- Eye redness
Certain symptoms of panuveitis demand urgent medical evaluation. Sudden onset of severe eye pain, significant vision loss or blurring, and the appearance of flashes of light or a sudden increase in floaters should prompt you to see a retina specialist or go to the emergency room immediately. Eye redness that does not improve, or the appearance of a white pupillary reflex, also requires immediate attention.
A particularly dangerous form called seasonal hyperacute panuveitis (SHAPU) affects one eye with rapid and profound vision loss. SHAPU is an important cause of childhood blindness in one eye and can lead to devastating intraocular inflammation and loss of sight within a single week. Any child showing sudden eye pain with vision loss needs emergency ophthalmologic evaluation.
Diagnosis and Testing
Diagnosing panuveitis begins with a thorough eye examination by a retina specialist or uveitis specialist. The specialist will use a slit lamp to examine the front of the eye for signs of inflammation, such as inflammatory cells floating in the aqueous humor. They will also look for deposits on the inner surface of the cornea called keratic precipitates.
The back of the eye is evaluated using dilated fundus examination and specialized imaging. The specialist looks for signs of choroidal inflammation, retinal involvement, vitreous haze from inflammatory cells, and other changes that indicate widespread disease.
Several imaging tests help retina specialists assess the extent and severity of panuveitis. Optical coherence tomography (OCT) produces detailed cross-sectional images of the retina and can detect complications like cystoid macular edema (swelling of the central retina). Fluorescein angiography uses a special dye to evaluate blood flow and leakage in the retinal vessels.
Because panuveitis is often linked to systemic diseases, blood tests and other laboratory studies are commonly ordered. These may include tests for sarcoidosis, Behcet disease, tuberculosis, syphilis, and various autoimmune markers. In some cases, a sample of fluid from inside the eye may be analyzed to identify infectious causes.
Determining what is causing panuveitis is critical for guiding treatment. The specialist may refer you to a rheumatologist, infectious disease doctor, or other specialist to investigate potential systemic conditions. Chest imaging may be performed to check for sarcoidosis or tuberculosis. A detailed medical history, including travel history and prior infections, helps narrow down possible causes.
In a significant number of cases, no underlying cause is identified despite thorough testing. These idiopathic cases still require treatment to control inflammation and prevent complications.
Treatment Options
Corticosteroids are the most common initial treatment for panuveitis in the acute setting. These powerful anti-inflammatory medications can be delivered in several ways. Topical steroid eye drops treat inflammation in the front of the eye. Periocular injections (injections around the eye) deliver medication closer to the affected tissues. Systemic oral steroids, such as prednisone, are used when inflammation is severe or affects both eyes.
While corticosteroids are effective at controlling acute inflammation, long-term use carries significant side effects. These include increased eye pressure (which can lead to glaucoma), cataract formation, weight gain, elevated blood sugar, and bone thinning. For this reason, retina specialists typically use corticosteroids to achieve initial control and then transition to steroid-sparing therapies.
For patients who need ongoing treatment, traditional immunosuppressive medications help control inflammation while reducing dependence on steroids. Commonly used drugs include methotrexate, mycophenolate mofetil, and azathioprine. These medications work by broadly suppressing the immune system's inflammatory response.
These drugs require regular monitoring through blood tests because they can affect liver function, kidney function, and blood cell counts. It often takes several weeks for immunosuppressive medications to reach full effectiveness, so steroids may be used concurrently during the transition period.
Current steroid-sparing therapies increasingly focus on targeting specific immunologic pathways. One of the most important is the tumor necrosis factor-alpha (TNF-alpha) pathway. TNF-alpha inhibitors are biologic medications that bind to TNF-alpha, a key inflammatory protein, and block its activity.
Adalimumab (Humira, AbbVie) is a monoclonal antibody that targets TNF-alpha. It was approved by the FDA in July 2016 for the treatment of adults with noninfectious intermediate, posterior, and panuveitis. In October 2018, the indication was expanded to include children ages 2 and older based on results of the SYCAMORE study. Adalimumab is given as a subcutaneous injection (an injection under the skin), typically every two weeks.
For patients with chronic noninfectious panuveitis, sustained-release steroid implants offer long-term local therapy. Retisert (fluocinolone acetonide intravitreal implant, 0.59 mg, Bausch and Lomb) is surgically placed inside the eye and releases medication for approximately three years. It was approved by the FDA in 2005 for noninfectious intermediate uveitis, posterior uveitis, and panuveitis.
Iluvien (fluocinolone acetonide intravitreal implant), a smaller implant that is injected rather than surgically placed, was approved by the FDA in April 2025 for chronic noninfectious uveitis of the posterior segment. It delivers continuous micro-dose steroid therapy for up to 36 months. Xipere (triamcinolone acetonide injectable suspension) uses a suprachoroidal delivery route, placing the medication in the space between the choroid and sclera. This approach achieves high drug concentrations at the retina while potentially lowering the risk of steroid-induced cataracts and elevated eye pressure.
Research into new treatments for panuveitis continues. Brepocitinib, an oral dual selective TYK2/JAK1 inhibitor from Priovant Therapeutics, is currently in a Phase III registrational trial for noninfectious uveitis. In September 2024, Priovant announced that brepocitinib received Fast Track Designation from the FDA, which is designed to speed the development and review of drugs for serious conditions. If approved, it could provide a new oral option for managing this challenging disease.
What to Expect
Treatment for panuveitis is often a gradual process. Initial corticosteroid therapy may provide noticeable improvement within days to weeks. Transitioning to steroid-sparing medications takes longer, sometimes several months before the full effect is achieved. Your retina specialist will monitor you with frequent follow-up visits during this period, adjusting medications as needed.
Regular eye exams are essential to track inflammation levels and watch for complications. Expect visits every few weeks during active inflammation, with the interval between visits gradually lengthening as the condition stabilizes.
Panuveitis can lead to several serious complications if not adequately controlled. Cystoid macular edema (swelling in the central part of the retina) is a common cause of vision loss in patients with uveitis. Cataracts (clouding of the eye's natural lens) can develop from both the inflammation itself and from corticosteroid treatment. Glaucoma (elevated eye pressure that damages the optic nerve) is another significant risk.
Other possible complications include:
- Band keratopathy, a calcium buildup on the cornea
- Vitreous opacities, which are clumps of inflammatory cells in the gel of the eye
- Retinal scarring or damage from prolonged inflammation
- Synechiae, which are adhesions between the iris and lens or cornea
The long-term prognosis for panuveitis varies depending on the underlying cause, severity, and how quickly treatment begins. Some patients achieve long-term remission and can eventually taper off medications. Others require ongoing treatment to prevent flare-ups. Early diagnosis and aggressive treatment improve the chances of preserving vision.
Patients with an identified and treatable underlying cause, such as an infectious agent, may have a better prognosis once the infection is controlled. Those with chronic autoimmune-related panuveitis typically need long-term management with immunosuppressive therapy or biologic agents.
Living with Panuveitis
Panuveitis can follow a relapsing and remitting course, meaning periods of controlled disease may be interrupted by flare-ups. Learning to recognize early symptoms of a flare, such as increasing sensitivity to light, mild blurring, or new floaters, allows you to contact your retina specialist promptly. Early treatment of flare-ups is important for preventing cumulative damage.
Keeping a consistent medication schedule is critical. Missing doses of immunosuppressive or biologic medications can increase the risk of recurrence. If you experience side effects from your medications, discuss them with your specialist rather than stopping treatment on your own.
Because panuveitis is frequently associated with systemic diseases, many patients benefit from coordinated care among multiple specialists. A rheumatologist may manage an underlying autoimmune condition. An infectious disease specialist may be involved if an infection is the cause. Your primary care doctor should be aware of your condition and any immunosuppressive medications you are taking.
Good communication between your retina specialist and other doctors helps ensure that treatments for your eye condition and any systemic disease work together without conflicting.
Wearing sunglasses can help manage photophobia, especially during flare-ups. Keeping all scheduled eye appointments is essential even when your eyes feel fine, because inflammation can be present without obvious symptoms. If you smoke, stopping may help reduce inflammation and improve treatment response.
Maintaining a healthy lifestyle supports your overall immune health. Regular exercise, a balanced diet, and adequate sleep can complement your medical treatment, though these measures are not a substitute for prescribed therapy.
When to See a Retina Specialist
Seek immediate evaluation from a retina specialist or go to the emergency room if you experience sudden severe eye pain, rapid vision loss, a sudden increase in floaters, flashes of light, or a curtain or shadow moving across your vision. These symptoms may indicate a serious flare or complication that requires urgent treatment. Do not wait to see if symptoms improve on their own.
If you have been diagnosed with a condition associated with panuveitis, such as sarcoidosis or Behcet disease, ask your doctor about baseline eye screening with a retina specialist. Patients with known autoimmune diseases should have regular comprehensive eye exams even in the absence of symptoms. Optometrists and primary care doctors can screen for signs of uveitis and refer you to a retina specialist for further evaluation and treatment when needed.
Questions and Answers
The answer depends on the underlying cause. When panuveitis is caused by a treatable infection, resolving the infection can lead to resolution of the eye inflammation. However, in many cases, particularly those related to autoimmune conditions or idiopathic causes, panuveitis is a chronic condition that is managed rather than cured. The goal of treatment is to control inflammation, prevent complications, and preserve as much vision as possible over the long term.
Treatment duration varies widely among patients. Some people achieve remission and can gradually taper off medications under close supervision by their retina specialist. Others require years of maintenance therapy to keep inflammation under control. Your specialist will make decisions about treatment duration based on your response, the severity of your disease, and whether the underlying cause has been addressed. It is important not to stop medications without guidance from your specialist, as this can trigger a flare-up.
Panuveitis can affect one or both eyes. Bilateral involvement (both eyes) is common, especially when the cause is a systemic condition like sarcoidosis or Behcet disease. Some forms, such as seasonal hyperacute panuveitis, tend to affect only one eye. Even if only one eye is currently involved, your retina specialist will monitor both eyes because inflammation can develop in the fellow eye over time.
Long-term immunosuppressive therapy does carry risks. Corticosteroids can cause cataracts, elevated eye pressure, weight gain, and bone thinning. Traditional immunosuppressives like methotrexate and mycophenolate mofetil require regular blood monitoring to check liver function, kidney function, and blood counts. Biologic agents like adalimumab (Humira) may increase susceptibility to certain infections. Your retina specialist and other treating doctors will weigh these risks against the risk of uncontrolled inflammation, which can cause permanent vision loss.
Yes, children can develop panuveitis, though it is less common than in adults. Uveitis overall occurs in about 30 per 100,000 children compared to 93 per 100,000 adults (AAO). Panuveitis and posterior uveitis together account for a meaningful proportion of pediatric uveitis cases (AAO). Children with uveitis need prompt evaluation and treatment because their developing eyes are particularly vulnerable to complications. Adalimumab (Humira) has been approved for children ages 2 and older with noninfectious uveitis, providing an important treatment option for younger patients.